Skip to Main Content

Paper Details

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Clin Cancer Res
39
2021
-mutant cells, ARAF, BRAF, CRAF, KRAS, KRAS mutants, LXH254, MAPK, MAPK-Driven Tumors, NRAS mutants, RAF, RAF paralogs, RAS, RAS-mutant cells, RAS-mutant lines, RAS-mutant tumors, cancer, cancer-derived cell lines, dabrafenib, isogenic, mutant K/NRAS, parental lines
Author NameAffiliation
Peter AspesiNovartis Institutes for Biomedical Research
Felipa A MapaNovartis Institutes for Biomedical Research
Peter S HammermanNovartis Institutes for Biomedical Research
Peter S HammermanNovartis Institutes for Biomedical Research
Giordano CaponigroNovartis Institutes for Biomedical Research
  • 1 - 5

Datasets

Release 1.2